DRTG(SH:600329)2016-10-30 16:00Financial Performance - Operating revenue decreased by 5.64% to CNY 4,741,439,058.51 for the period from January to September[9] - Net profit attributable to shareholders increased by 4.25% to CNY 349,272,916.40 for the period from January to September[9] - Total revenue for Q3 2016 was CNY 1,494,966,749.58, a decrease of 10.1% compared to CNY 1,663,330,102.89 in Q3 2015[39] - Year-to-date revenue from January to September 2016 was CNY 4,741,439,058.51, down 5.6% from CNY 5,025,011,031.27 in the same period last year[39] - The company reported a net profit of CNY 339,650,766.49 for the first nine months of 2016, slightly up from CNY 337,781,929.03 in the same period last year, an increase of 0.6%[40] - Net profit for Q3 2016 was CNY 89,323,147.74, down from CNY 94,883,118.76 in the same quarter last year, representing a decline of 5.9%[41] - The company reported a total profit of CNY 97,446,168.22 for Q3 2016, compared to CNY 111,746,271.31 in Q3 2015, reflecting a decrease of 12.7%[40] Assets and Liabilities - Total assets increased by 2.25% to CNY 6,205,577,883.97 compared to the end of the previous year[8] - Total liabilities decreased to CNY 1,896,320,226.78 from CNY 1,963,702,937.25 at the beginning of the year, reflecting a reduction of approximately 3.4%[34] - Current liabilities totaled CNY 1,762,188,229.76, down from CNY 1,840,322,777.15 at the start of the year, indicating a decrease of about 4.3%[34] - Non-current assets increased to CNY 2,170,772,932.44 from CNY 2,070,356,522.01, representing a growth of approximately 4.5%[34] - As of September 30, 2016, the total current assets amounted to CNY 4,034,804,951.53, an increase from CNY 3,998,520,575.72 at the beginning of the year, reflecting a growth of approximately 0.91%[32] Cash Flow - Net cash flow from operating activities increased by 9.90% to CNY 189,600,777.82 for the period from January to September[8] - Cash inflow from operating activities for the first nine months of 2016 was CNY 4,060,178,380.47, a decrease of 5.9% from CNY 4,315,231,518.83 in the same period of 2015[45] - Cash inflow from investment activities for the first nine months of 2016 was CNY 25,917,313,355.08, significantly higher than CNY 15,669,069,247.11 in the same period of 2015, marking an increase of 65.3%[46] - Cash inflow from financing activities for the first nine months of 2016 totaled CNY 14,097,956,454.80, compared to CNY 30,941,154,099.24 in the same period of 2015, indicating a decrease of 54.4%[46] - The ending cash and cash equivalents balance as of September 30, 2016, was CNY 839,182,407.79, down from CNY 1,027,557,070.02 at the end of September 2015[46] Shareholder Information - The number of shareholders reached 34,826 at the end of the reporting period[15] - The largest shareholder, Tianjin Pharmaceutical Group Co., Ltd., holds 43.065% of the shares[15] Investment and Financial Activities - Investment income from associates surged by 374% to ¥103,186,891.25, reflecting increased returns from investments[21] - The company reported a non-recurring profit of CNY 3,299,593.65 for the period from July to September[16] - The company’s investment income for Q3 2016 was CNY 42,831,956.32, a decrease from CNY 72,609,604.49 in Q3 2015, representing a decline of 41.0%[40] Commitments and Compliance - The company committed to resolving related party transactions and competition issues with its controlling shareholder, Tianjin Pharmaceutical Group[23] - The company has established a long-term commitment to avoid related party transactions with its controlling shareholder, ensuring fair and reasonable pricing[28] - The company has pledged to compensate for any losses incurred due to litigation related to Jinyao Amino Acids, ensuring long-term accountability[29] - The company reported that it strictly adhered to all commitments as of the announcement date, demonstrating compliance and accountability[27]